<DOC>
	<DOC>NCT00070642</DOC>
	<brief_summary>To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.</brief_summary>
	<brief_title>CPG 7909 Injection in Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically or cytologically confirmed melanoma that is metastatic. Measurable disease according to the RECIST criteria. Karnofsky Performance Status of &gt; 70. Prior treatment with antineoplastic biologic or chemotherapy for recurrent or metastatic disease (except one course of adjuvant immunotherapy and/or adjuvant chemotherapy other than DTIC). Suspected or known CNS metastases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Immunotherapy, skin cancer</keyword>
</DOC>